Omeros (OMER) Competitors $3.08 -0.12 (-3.75%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$3.06 -0.02 (-0.49%) As of 07/7/2025 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock OMER vs. NKTR, ASMB, CPIX, LLY, JNJ, ABBV, MRK, PFE, BMY, and ZTSShould you be buying Omeros stock or one of its competitors? The main competitors of Omeros include Nektar Therapeutics (NKTR), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol Myers Squibb (BMY), and Zoetis (ZTS). These companies are all part of the "pharmaceuticals" industry. Omeros vs. Its Competitors Nektar Therapeutics Assembly Biosciences Cumberland Pharmaceuticals Eli Lilly and Company Johnson & Johnson AbbVie Merck & Co., Inc. Pfizer Bristol Myers Squibb Zoetis Omeros (NASDAQ:OMER) and Nektar Therapeutics (NASDAQ:NKTR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership. Do analysts prefer OMER or NKTR? Omeros presently has a consensus target price of $18.00, suggesting a potential upside of 484.42%. Nektar Therapeutics has a consensus target price of $84.17, suggesting a potential upside of 258.61%. Given Omeros' higher probable upside, equities analysts plainly believe Omeros is more favorable than Nektar Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Omeros 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.83Nektar Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has higher earnings and valuation, OMER or NKTR? Nektar Therapeutics has higher revenue and earnings than Omeros. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOmerosN/AN/A-$156.82M-$2.65-1.16Nektar Therapeutics$98.43M2.96-$118.96M-$9.60-2.44 Which has more risk & volatility, OMER or NKTR? Omeros has a beta of 2.16, suggesting that its share price is 116% more volatile than the S&P 500. Comparatively, Nektar Therapeutics has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Do institutionals & insiders have more ownership in OMER or NKTR? 48.8% of Omeros shares are held by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are held by institutional investors. 12.9% of Omeros shares are held by company insiders. Comparatively, 3.7% of Nektar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is OMER or NKTR more profitable? Omeros has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -152.49%. Omeros' return on equity of 0.00% beat Nektar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets OmerosN/A N/A -59.68% Nektar Therapeutics -152.49%-329.54%-55.24% Does the media prefer OMER or NKTR? In the previous week, Nektar Therapeutics had 15 more articles in the media than Omeros. MarketBeat recorded 15 mentions for Nektar Therapeutics and 0 mentions for Omeros. Omeros' average media sentiment score of 0.52 beat Nektar Therapeutics' score of 0.40 indicating that Omeros is being referred to more favorably in the media. Company Overall Sentiment Omeros Positive Nektar Therapeutics Neutral SummaryOmeros beats Nektar Therapeutics on 8 of the 15 factors compared between the two stocks. Get Omeros News Delivered to You Automatically Sign up to receive the latest news and ratings for OMER and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OMER and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OMER vs. The Competition Export to ExcelMetricOmerosMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$187.50M$10.52B$5.52B$9.02BDividend YieldN/A2.07%5.24%4.08%P/E Ratio-1.1616.9127.1920.04Price / SalesN/A28.87395.22100.83Price / CashN/A23.9726.2128.59Price / Book-0.983.637.925.55Net Income-$156.82M$235.43M$3.17B$248.49M7 Day Performance3.70%-0.32%1.79%4.87%1 Month Performance-18.30%-0.33%1.28%6.63%1 Year Performance-20.82%-10.48%33.32%20.38% Omeros Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OMEROmeros3.5492 of 5 stars$3.08-3.8%$18.00+484.4%-20.3%$187.50MN/A-1.16210NKTRNektar Therapeutics4.562 of 5 stars$25.84+0.3%$84.17+225.7%+21.3%$320.67M$98.43M-2.69220Gap UpHigh Trading VolumeASMBAssembly Biosciences3.7423 of 5 stars$18.12+4.7%$33.00+82.1%+40.5%$138.44M$28.52M-2.91100High Trading VolumeCPIXCumberland Pharmaceuticals0.5503 of 5 stars$3.35+28.8%N/A+107.5%$50.12M$37.87M-13.4080LLYEli Lilly and Company4.9869 of 5 stars$779.35+0.5%$1,011.61+29.8%-15.5%$738.62B$45.04B63.4147,000Trending NewsOptions VolumeJNJJohnson & Johnson4.9545 of 5 stars$152.58+0.1%$170.88+12.0%+6.0%$367.12B$88.82B16.97138,100Positive NewsABBVAbbVie4.9205 of 5 stars$185.80+1.9%$211.29+13.7%+12.1%$328.20B$56.33B79.0655,000Trending NewsMRKMerck & Co., Inc.4.9969 of 5 stars$79.19+0.1%$109.19+37.9%-36.0%$198.85B$63.92B11.5375,000Positive NewsPFEPfizer4.9745 of 5 stars$24.27+0.3%$29.17+20.2%-10.1%$137.98B$63.63B17.5981,000Positive NewsBMYBristol Myers Squibb4.8983 of 5 stars$46.35flat$58.00+25.1%+17.2%$94.33B$48.30B17.3634,300Positive NewsZTSZoetis4.8248 of 5 stars$155.86-0.2%$212.13+36.1%-10.3%$69.39B$9.26B27.9813,800Positive News Related Companies and Tools Related Companies NKTR Alternatives ASMB Alternatives CPIX Alternatives LLY Alternatives JNJ Alternatives ABBV Alternatives MRK Alternatives PFE Alternatives BMY Alternatives ZTS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OMER) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredInstant Cash (in 4 clicks)Since 1973, Wall Street has quietly used a strange little pricing quirk to cash flow billions. Now, for the...Awesomely, LLC | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Omeros Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Omeros With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
